ArticleCureus2024
Comparative Analysis of Biochemical and Lipid Profile Markers at Different Stages of Lung Cancer: A Cross-Sectional Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammation, metabolic dysregulation, and changes in biochemical markers are closely associated with the progression of lung cancer. This study focuses on evaluating serum parathyroid hormone (PTH), C-reactive protein (CRP), lipid profile parameters, and interleukin-6 (IL-6) in relation to the stages of lung cancer, exploring their potential as biomarkers for assessing disease severity.
methodsA total of 160 lung cancer patients were selected for a cross-sectional study and equally distributed into four clinical stages (Stages 1-4). PTH, CRP, low-density lipoproteins (LDLs), high-density lipoproteins (HDLs), triacylglycerides (TAGs), and IL-6 were analyzed in serum by the enzyme-linked immunosorbent assay, chemiluminescent immunoassay, and enzymatic techniques. Statistical analysis included analysis of variance with post hoc Tukey's test and Pearson correlation analysis for body mass index (BMI) and Eastern Cooperative Oncology Group (ECOG) performance status.
resultsPTH levels increased significantly as the disease progressed (Stage 1: 10.8 ± 2.5 pg/mL; Stage 4: 498 ± 89.4 pg/mL; p < 0.001). Similarly, CRP (Stage 1: 5.8 ± 1.2 mg/L; Stage 4: 8.6 ± 2.4 mg/L; p = 0.004) and IL-6 (Stage 1: 3.8 ± 0.9 pg/mL; Stage 4: 8.5 ± 2.1 pg/mL; p < 0.001) levels showed significant increases, indicating elevated systemic inflammation in the advanced stages. Lipid profile analysis revealed a decrease in HDL levels (p = 0.042) and an increase in TAG levels (p = 0.031), while LDL levels did not show statistically significant variations (p = 0.085). The ECOG performance status significantly deteriorated with advancing stages (p = 0.001) and was strongly correlated with BMI (r = 0.915; p < 0.001).
conclusionLung cancer progression is strongly linked to elevated levels of PTH, CRP, and IL-6, alongside dysregulated lipid profiles. The interplay of systemic inflammation and metabolic alterations underscores key pathophysiological mechanisms underlying the disease. Emerging evidence suggests that PTH and IL-6 hold promise as potential biomarkers for assessing disease severity and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.